- Oops!Something went wrong.Please try again later.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Prothena (PRTA), a company that currently holds a Momentum Style Score of B. We also talk about price change and earnings estimate revisions, two of the main aspects of the Momentum Style Score.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Prothena currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market?
In order to see if PRTA is a promising momentum pick, let's examine some Momentum Style elements to see if this drug developer holds up.
Looking at a stock's short-term price activity is a great way to gauge if it has momentum, since this can reflect both the current interest in a stock and if buyers or sellers have the upper hand at the moment. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For PRTA, shares are up 4.77% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 1.92% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 22.88% compares favorably with the industry's 1.83% performance as well.
While any stock can see a spike in price, it takes a real winner to consistently outperform the market. Shares of Prothena have increased 23.63% over the past quarter, and have gained 486.1% in the last year. In comparison, the S&P 500 has only moved 7.15% and 37.06%, respectively.
Investors should also pay attention to PRTA's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. PRTA is currently averaging 398,020 shares for the last 20 days.
The Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with PRTA.
Over the past two months, 5 earnings estimates moved higher compared to none lower for the full year. These revisions helped boost PRTA's consensus estimate, increasing from -$1.23 to $1.45 in the past 60 days. Looking at the next fiscal year, 5 estimates have moved upwards while there have been no downward revisions in the same time period.
Taking into account all of these elements, it should come as no surprise that PRTA is a #2 (Buy) stock with a Momentum Score of B. If you've been searching for a fresh pick that's set to rise in the near-term, make sure to keep Prothena on your short list.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Prothena Corporation plc (PRTA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research